Skip to main content
Journal cover image

The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.

Publication ,  Journal Article
Paul, B; Zhao, Y; Loitsch, G; Feinberg, D; Mathews, P; Barak, I; Dupuis, M; Li, Z; Rein, L; Wang, E; Kang, Y
Published in: Cancer Med
August 2020

We determined the impact of bone marrow fibrosis (BMF) on the clinical outcomes of newly diagnosed multiple myeloma (NDMM) patients in the current era of myeloma therapy. A total of 393 MM patients were included in the final analysis. The median followup was 83 months (range: 3.9 to 212 months). BMF was noted in 122 (48.2%) evaluable patients. Median progression free survival (PFS) in patients without BMF was 30.2 (95% CI: 24.7-38.0) months, and 21.1 (95% CI: 18.8-27.5) months in patients with BMF present (P = .024). Median overall survival (OS) was 61.2 (95% CI: 51.5-81.2) months in patients without BMF, and 45.1 (95% CI: 38.7-57.0) months in patients with BMF (P = .0048). A subset of 99 patients had their bone marrow biopsies stained for JAK1 and JAK2 by immunohistochemistry. Of these samples 67 (67.7%) patients had detectable JAK2 expression predominantly noted on bone marrow megakaryocytes. JAK2 expression correlated with myeloma disease stage (P = .0071). Our study represents the largest dataset to date examining the association of BMF with prognosis in the era of novel therapies and widespread use of hematopoietic stem cell transplant (HSCT). Our data suggest that MM patients with BMF (particularly those with extensive BMF) have a poorer prognosis even when treated with immunomodulatory agents and proteasome inhibitors.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

August 2020

Volume

9

Issue

16

Start / End Page

5869 / 5880

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndecan-1
  • Retrospective Studies
  • Proteasome Inhibitors
  • Progression-Free Survival
  • Prognosis
  • Primary Myelofibrosis
  • Multiple Myeloma
  • Middle Aged
  • Megakaryocytes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Paul, B., Zhao, Y., Loitsch, G., Feinberg, D., Mathews, P., Barak, I., … Kang, Y. (2020). The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. Cancer Med, 9(16), 5869–5880. https://doi.org/10.1002/cam4.3265
Paul, Barry, Yue Zhao, Gavin Loitsch, Daniel Feinberg, Parker Mathews, Ian Barak, Megan Dupuis, et al. “The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors.Cancer Med 9, no. 16 (August 2020): 5869–80. https://doi.org/10.1002/cam4.3265.
Paul B, Zhao Y, Loitsch G, Feinberg D, Mathews P, Barak I, Dupuis M, Li Z, Rein L, Wang E, Kang Y. The impact of bone marrow fibrosis and JAK2 expression on clinical outcomes in patients with newly diagnosed multiple myeloma treated with immunomodulatory agents and/or proteasome inhibitors. Cancer Med. 2020 Aug;9(16):5869–5880.
Journal cover image

Published In

Cancer Med

DOI

EISSN

2045-7634

Publication Date

August 2020

Volume

9

Issue

16

Start / End Page

5869 / 5880

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Syndecan-1
  • Retrospective Studies
  • Proteasome Inhibitors
  • Progression-Free Survival
  • Prognosis
  • Primary Myelofibrosis
  • Multiple Myeloma
  • Middle Aged
  • Megakaryocytes